Sökning: onr:"swepub:oai:gup.ub.gu.se/65277" > Rosuvastatin in old...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05422naa a2200949 4500 | |
001 | oai:gup.ub.gu.se/65277 | |
003 | SwePub | |
008 | 240528s2007 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/652772 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa07062012 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Kjekshus, John4 aut |
245 | 1 0 | a Rosuvastatin in older patients with systolic heart failure. |
264 | 1 | c 2007 |
520 | a BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.) | |
653 | a Aged | |
653 | a Cardiovascular Diseases | |
653 | a epidemiology | |
653 | a mortality | |
653 | a Female | |
653 | a Fluorobenzenes | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Follow-Up Studies | |
653 | a Heart Failure | |
653 | a drug therapy | |
653 | a etiology | |
653 | a Hospitalization | |
653 | a statistics & numerical data | |
653 | a Humans | |
653 | a Hydroxymethylglutaryl-CoA Reductase Inhibitors | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Male | |
653 | a Middle Aged | |
653 | a Myocardial Ischemia | |
653 | a complications | |
653 | a Proportional Hazards Models | |
653 | a Pyrimidines | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Single-Blind Method | |
653 | a Sulfonamides | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Systole | |
653 | a Treatment Outcome | |
700 | 1 | a Apetrei, Eduard4 aut |
700 | 1 | a Barrios, Vivencio4 aut |
700 | 1 | a Böhm, Michael4 aut |
700 | 1 | a Cleland, John G F4 aut |
700 | 1 | a Cornel, Jan H4 aut |
700 | 1 | a Dunselman, Peter4 aut |
700 | 1 | a Fonseca, Cândida4 aut |
700 | 1 | a Goudev, Assen4 aut |
700 | 1 | a Grande, Peer4 aut |
700 | 1 | a Gullestad, Lars4 aut |
700 | 1 | a Hjalmarson, Åke,d 1937u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xhjala |
700 | 1 | a Hradec, Jaromir4 aut |
700 | 1 | a Jánosi, András4 aut |
700 | 1 | a Kamenský, Gabriel4 aut |
700 | 1 | a Komajda, Michel4 aut |
700 | 1 | a Korewicki, Jerzy4 aut |
700 | 1 | a Kuusi, Timo4 aut |
700 | 1 | a Mach, François4 aut |
700 | 1 | a Mareev, Vyacheslav4 aut |
700 | 1 | a McMurray, John J V4 aut |
700 | 1 | a Ranjith, Naresh4 aut |
700 | 1 | a Schaufelberger, Maria,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xscmar |
700 | 1 | a Vanhaecke, Johan4 aut |
700 | 1 | a van Veldhuisen, Dirk J4 aut |
700 | 1 | a Waagstein, Finn,d 1938u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xwaafi |
700 | 1 | a Wedel, Hans4 aut |
700 | 1 | a Wikstrand, John,d 1938u Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory4 aut0 (Swepub:gu)xwikjo |
710 | 2 | a Göteborgs universitetb Wallenberglaboratoriet4 org |
773 | 0 | t The New England journal of medicineg 357:22, s. 2248-61q 357:22<2248-61x 1533-4406 |
856 | 4 8 | u https://gup.ub.gu.se/publication/65277 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa0706201 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy